| HER-2阳性胃癌的研究进展 |
| |
| 引用本文： | 牛 悦,白建平,卢建跃. HER-2阳性胃癌的研究进展[J]. 医学信息, 2019, 0(1): 44-46. DOI: 10.3969/j.issn.1006-1959.2019.01.015 |
| |
| 作者姓名： | 牛 悦 白建平 卢建跃 |
| |
| 作者单位： | 解放军第二五四医院普外科，天津 300143 |
| |
| 摘 要： | 胃癌是我国最常见的消化道恶性肿瘤之一，随着我国社会经济的发展、人们食物谱的改变，我国的胃癌发病率呈显著上升趋势。人类表皮生长因子受体2（HER-2）是一种原癌基因，在部分胃癌患者中存在高表达，针对HER-2的靶向治疗，可使HER-2阳性的晚期胃癌患者获得显著的生存收益。ToGA研究是胃癌靶向治疗史上的一座里程碑，它首次在大规模样本中证实看联合应用化疗药及曲妥珠单抗可有效延长患者生存期。本文就HER-2阳性胃癌的研究进展作一综述。
|
| 关 键 词： | 人类表皮生长因子受体2 胃癌 靶向治疗 |
Progress in Research of HER-2 Positive Gastric Cancer |
| |
| NIU Yue,BAI Jian-ping,LU Jian-yue. Progress in Research of HER-2 Positive Gastric Cancer[J]. Medical Information, 2019, 0(1): 44-46. DOI: 10.3969/j.issn.1006-1959.2019.01.015 |
| |
| Authors: | NIU Yue BAI Jian-ping LU Jian-yue |
| |
| Affiliation: | General Surgery,the 254th Hospital of Chinese PLA,Tianjin 300143,China |
| |
| Abstract: | Gastric cancer is one of the most common malignant tumors of the digestive tract in China. With the development of China's social economy and the changes in people's food spectrum, the incidence of gastric cancer in China has shown a significant upward trend. Human epidermal growth factor receptor 2 (HER-2) is a proto-oncogene that is highly expressed in some patients with gastric cancer. Targeted therapy against HER-2 can significantly improve HER-2 positive patients with advanced gastric cancer. Survival gains. The ToGA study is a milestone in the history of targeted therapy for gastric cancer. It was first demonstrated in large-scale samples that the combination of chemotherapeutic drugs and trastuzumab can effectively prolong patient survival. This article reviews the research progress of HER-2 positive gastric cancer. |
| |
| Keywords: | Human epidermal growth factor receptor-2 Gastric cancer Targeted therapy |
|
| 点击此处可从《医学信息》浏览原始摘要信息 |
|
点击此处可从《医学信息》下载免费的PDF全文 |
